Translation, Cross-cultural Adaptation and Validation of Ankylosing Spondylitis Disease Activity Score

A Datta1, MR Choudhury2, A Shahin3, N Islam4, S Ahmed5, S A Haq6, AK Ahmedullah7, A Islam8, SK Mondal9, I Hossain10

Abstract:

Ankylosing Spondylitis Disease Activity Score (ASDAS) is a very important tool for measuring disease activity in patients with axial spondyloarthritis (axSpA). This study was aimed to develop a culturally adapted, valid and reliable Bengali version of questionnaire for the ASDAS. The original English ASDAS was translated into Bangla and adapted in the local socio-cultural context, following standard international recommendations. Content validity of the adapted Bangla version was assessed by the item-level & scale level content validity indices (I-CVI & S-CVI). A total 120 patients with axSpA were assessed in the study. For construct validity, correlation between ASDAS with BASDAI, ESR, CRP, Maastricht enthesitis score, physician's global assessment and BASMI was assessed by Spearman's rank correlation coefficient. Internal consistency and test-retest reliability were assessed using Cronbach's alpha coefficient and intraclass correlation coefficient respectively. I-CVI for each item was 1 and S-CVI was 1. ASDAS-ESR and ASDAS-CRP showed strong correlation (Spearman's correlation coefficient >0.5) with BASDAI, ESR, MASES and physician global assessment of disease activity. The scale demonstrated excellent internal consistency (Cronhbach's alpha=0.703) and test-retest reliability (ICC=0.98). The adapted Bangla version of the ASDAS demonstrated acceptable psychometric properties (validity & reliability) in Bangladeshi patients with axSpA.

Key words: Ankylosing spondylitis, Spondyloarthritis, Adaptation, Validation, Consistency, Reliability, Correlation.

Introduction:

Spondyloarthritis (SpA) is a family of inflammatory disorders which includes ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpA), reactive arthritis (formerly called Reiter syndrome), psoriatic arthritis, SpA associated with Crohn's disease and ulcerative colitis, juvenile onset spondyloarthritis and undifferentiated spondyloarthritis10. AS and nr-axSpA are now considered as different stages on the spectrum of a clinical entity called axial spondyloarthritis10.

Two important tools for measuring disease activity in patients with axSpA are the Bath ankylosing spondylitis disease activity index (BASDAI) and the ASDAS. The BASDAI, published in 1994, comprises six questions and is fully a patient-reported measure11. The BASDAI does not weigh individual clinical manifestations, as the variables are simply summed, without taking the relative importance, redundancy and dependency into account. It also lacks specificity for inflammatory processes12. The ASDAS is a new composite index to assess disease activity in AS which was developed in 2009 by the Assessment of SpondyloArthritis international Society (ASAS) aiming to improve the construct validity of disease activity measures in axSpA13,14. The ASDAS has many advantages over BASDAI15-27. The ASDAS has been derived from three questions from the BASDAI (BASDAI question-2, 3 and 6) plus the patient global assessment of disease activity measures in axSpA13,14. The ASDAS has been extensively validated. This study aimed to develop a Bengali version of the ASDAS questionnaire and to assess its validity and reliability in Bangladeshi patients with axSpA.
Materials and Methods:

It was an observational study designed in two phases, phase-1 and phase-2. Phase-1 consisted of translation and cross-cultural adaptation of the original English ASDAS into Bengali following the recommendations of standard guidelines. Phase-2 consisted of assessment of the psychometric properties of the adapted Bengali version of the ASDAS, ie. testing its validity (content and construct validity) and reliability (internal consistency & test-retest reliability). We included adult Bangladeshi patients (>16 years) who were classified as AS according to modified New York criteria for AS or nr-axSpA according to ASAS classification criteria for nr-axSpA. Patients with pregnancy, morbidly sick patients who are unable to communicate, patients having injury on the lumbar vertebrae or femur, patients having previous history of fracture, mentally retarded patients, patients with overlap with other rheumatological diseases, malignancy and patients who were not willing to take part in the study were excluded.

Translation and adaptation of the English ASDAS questionnaire into Bengali were accomplished in five stages: forward translation, synthesis of Bengali version, back translation, expert committee review and test of the pre-final Bengali version. The expert committee reviewed and compared all the translations and the original English ASDAS. The committee verified the semantic, idiomatic, experiential and conceptual equivalence between the English and Bengali versions. Following this way, the pre-final Bengali questionnaire was developed. The pre-final Bengali version of the ASDAS was tested in a sample of 38 adult patients with axSpA. Each subject completing the questionnaire was interviewed to probe about what he or she thought was meant by each questionnaire item and the chosen response. This ensured that the adapted version had retained its equivalence in an applied situation.

Testing of the validity and reliability of the Bengali version of the questionnaire was carried out in 120 patients in the second phase. During statistical analysis a p-value of < 0.05 was considered significant. Content validity was assessed by the item-level content validity index (I-CVI) and the scale-level content validity index (S-CVI). Spearman's rank correlation coefficient (r) was used to demonstrate construct validity. Correlation coefficients of >0.50, 0.35-0.50 and <0.35 was considered strong, moderate and weak correlations respectively. Internal consistency was measured by Cronbach's alpha (a). An a of 0.7 or higher was acceptable to us. Test-retest reliability was assessed by demonstrating the correlation between the test responses and retest responses using intraclass correlation coefficient (r). An r of 0.7 or higher indicated good test-retest reliability.

Results:

During pretesting, several Bengali words were also put in front of the respondents for their understandability, chosen responses and any alternate suggestions. Summary of the understandability of the items has been represented in table 1.

During probing, items 1, 2 and 4 were understood by all (100% of the respondents). The expert committee decided to keep two Bangla options for the word "Morning stiffness" in the item 3 of English questionnaire and developed two options [3(1) and 3(2)] for pretesting. During pretesting, the first [3(1)] and second [3(2)] options for item 3 in the prefinal version were understood by 84% and 97% of the participants. Although very high percentages of the participants understood both the options, for the adapted version the expert committee decided to keep both the Bengali options besides one another in a single sentence so that all the target population could be able to understand the item. Thus, the items best understood and best chosen were compiled to produce the adapted version.

Content validity of the adapted version was assessed by four rheumatologists. Item-level content validity index (I-CVI) was found to be 1 (Table-II) for each item and scale-level content validity index (S-CVI) was therefore 1 by the averaging calculation method. Table-I depicts the rating of each item by each of the experts, corresponding I-CVIs and the S-CVI.

ASDAS-ESR showed strong correlation (Spearman's correlation coefficient >0.5) with BASDAI, ESR, MASES and physician global assessment of disease activity, but weak correlation with BASMI (table-III). ASDAS-CRP also showed strong correlation with BASDAI, ESR, MASES and physician global assessment of disease activity, but moderate correlation with BASMI (table-IV).

Rating by each expert (rheumatologist) for all 4 questions: 1= not relevant, 2= somewhat relevant, 3= quite relevant, 4= highly relevant; S-CVI/Ave = (1.0+1.0+1.0+1.0)/4=1.0; *I-CVI, item-level content validity index; I-CVI is the proportion of expert giving a rating of either 3 or 4; **S-CVI / Ave, scale-level content validity index, averaging calculation method; Proportion relevant, proportion of questions that are quite or highly relevant; Excellent content validity means S-CVI/Ave ≥ 0.9; Item, individual question.
Table-I: Understandability and chosen response in pretesting of items

| Item   | Understandable (n) | Understandable (%) | Not Understandable (n) | Understandable (%) | More suitable (n) | Both suitable (n, %) |
|--------|--------------------|--------------------|------------------------|--------------------|------------------|---------------------|
| Item-1 | 38                 | 100                | 00                     | 00                 | -                | -                   |
| Item-2 | 38                 | 100                | 00                     | 00                 | -                | -                   |
| Item-3 (1) | 32             | 84                 | 6                      | 16                 | 10, 26           | 2, 5                |
| Item-3 (2) | 36             | 97                 | 2                      | 3                  | 19, 50           |                     |
| Item-4 | 38                 | 100                | 00                     | 00                 | 00               | -                   |

n, number of patients; %, Percentage of patients; Item, individual question.

Table-II: Content validity of the Adapted Bangla Version of the ASDAS

| Item   | Rating by Expert 1 | Rating by Expert 2 | Rating by Expert 3 | Rating by Expert 4 | I-CVI* |
|--------|--------------------|--------------------|--------------------|--------------------|--------|
| Item-1 | 4                  | 4                  | 4                  | 4                  | 1.0    |
| Item-2 | 4                  | 4                  | 4                  | 3                  | 1.0    |
| Item-3 | 3                  | 4                  | 3                  | 4                  | 1.0    |
| Item-4 | 4                  | 4                  | 4                  | 4                  | 1.0    |

Proportion Relevant^ 4/4=1.0 4/4=1.0 4/4=1.0 4/4=1.0 Mean I-CVI 1.0

Table-III: Spearman rank correlation of ASDAS-ESR with BASDAI, ESR, CRP, PhGA, MASES and BASMI

| ASDAS-ESR 1 with | Correlation coefficient (r) | p-value |
|------------------|-----------------------------|---------|
| ASDAS-ESR 2      | 0.980                       | <0.001  |
| BASDAI           | 0.722                       | <0.001  |
| ESR              | 0.827                       | <0.001  |
| CRP              | 0.662                       | <0.001  |
| PGA              | 0.865                       | <0.001  |
| MASES            | 0.599                       | <0.001  |
| BASMI            | 0.294                       | 0.001   |

Table-IV: Spearman rank correlation of ASDAS-CRP with BASDAI, ESR, CRP, PhGA, MASES and BASMI

| ASDAS-CRP 1 with | Correlation coefficient (r) | p-value |
|------------------|-----------------------------|---------|
| ASDAS-CRP 2      | 0.980                       | <0.001  |
| BASDAI           | 0.718                       | <0.001  |
| ESR              | 0.688                       | <0.001  |
| CRP              | 0.788                       | <0.001  |
| PGA              | 0.816                       | <0.001  |
| MASES            | 0.564                       | <0.001  |
| BASMI            | 0.362                       | <0.001  |

ASDAS, Ankylosing spondylitis disease activity score; ASDAS-ESR 1, ASDAS-ESR calculated at first visit of patient; ASDAS-ESR 2, ASDAS-ESR calculated at second visit of patient; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; PGA, Physician global assessment of disease activity; MASES, Maastricht enthesis score; BASMI, Bath ankylosing spondylitis meterological index; r, Spearman rank correlation coefficient; p-value <0.05 means significant.

Discussion:

The ASDAS is one of the most commonly used assessment and monitoring tools for the patients with axSpA. The ASAS has recommended BASDAI for measuring disease activity in patients with ankylosing spondylitis in 1994. But BASDAI does not weigh individual clinical manifestations, as the variables are simply summed, without taking the relative importance into account. Inflammatory markers are ignored for...
assessing disease activity in BASDAI. Therefore, ASDAS, as a new composite assessment tool for disease activity and cut-off values for disease severity was developed by the ASAS group of experts in 2009 with the aim to improve the construct validity of disease activity measures in AS.

ASDAS is composed of four questions. Three of the questions have been derived from BASDAI. The fourth question stands for patient's global assessment for disease activity. Although both BASDAI and ASDAS have been extensively validated in different countries, none of them were validated in our country. Therefore, with these four questions, the 'ASDAS questionnaire' was collected together and was regarded as an original English questionnaire for translation with cultural adaptation into Bangla and its validation in assessing diseases activity in patients with axSpA in our country.

In our study, we enrolled 120 patients with axSpA including AS and nr-axSpA according to the modified New York criteria for AS29 and the ASAS criteria for axSpA30. Inflammatory back pain which was an essential feature required for modified New York criteria for AS was determined according to the ASAS expert criteria for inflammatory back pain31. Radiographic sacroiliitis was determined according to New York grading of radiographic sacroilitis32.

During cross-cultural adaptation of the original ASDAS English questionnaire we concentrated mainly on semantic and conceptual forms of equivalence. As the items in the original English questionnaire do not represent any idiom or experience that does not prevail or is uncommon in the Bangladeshi culture, no modification was required to achieve conceptual and experiential forms of equivalence. For the purpose of facilitation of probing, two translations of item 3 were retained as an alternative to each other in the prefinal version approved by the expert committee. The expert committee again reviewed after pretesting among thirty eight patients with axSpA and although both translations were understood by a high percentage of respondents, the committee decided to keep two alternate words in a single sentence so that it could be understood by all. Understandability and chosen responses were also tested two alternate Bangla translations of a word in item 1 and 4. The best understood (100%) and the best chosen items by the participants were chosen from the prefinal version to constitute the adapted version.

The adapted version of the scale was found to have acceptable content validity in the form of ICVI (=1), S-CVI (=1). At the first visit, ASDAS questionnaire was applied to the patients to record the individual scores of four questions by patient himself/herself (self administered) and the investigator calculated the total score (ASDAS-ESR 1 and ASDAS-CRP 1) by applying the ASDAS calculator and using the values of individual questions and acute phase reactants (ESR and CRP). The patients' BASDAI score and BASMI scores were also measured at the first visit. Retest of the patient was conducted after seven days. The patients were instructed to come back for second visit with ESR and CRP values measured again seven days later. In the retest, individual item score and total ASDAS scores (ASDAS-ESR 2 and ASDAS-CRP 2) was determined.

Statistical analysis showed a strong correlation of ASDAS-ESR 1 with ASDAS-ESR 2 \[rs=0.980, p=<0.001\], BASDAI \[rs=0.722, p=<0.001\], ESR \[rs=0.827, p=<0.001\], CRP \[rs=0.662, p=<0.001\], PGA \[rs=0.865, p=<0.001\] and MASES \[rs=0.599, p=<0.001\] but poor correlation with BASMI \[rs=0.294, p=0.001\]. Similarly, ASDAS-CRP 1 showed strong correlation with ASDAS-CRP 2 \[rs=0.980, p=<0.001\], BASDAI \[rs=0.718, p=<0.001\], ESR \[rs=0.688, p=<0.001\], CRP \[rs=0.788, p=<0.001\], PGA \[rs=0.816, p=<0.001\] and MASES \[rs=0.564, p=<0.001\], and poor but significant correlation with BASMI \[rs=0.362, p=<0.001\]. Strong correlation of ASDAS score with ESR, CRP, PGA and MASES indicates that value of these clinical and laboratory parameters correlate with disease activity (inflammation). On the other hand, BASMI may not always correlate with disease activity. Not only generalized inflammation, but also previous damage (without current inflammation) also affect BASMI.

A study in China, aim of which was to validate the ASDAS, showed high correlation of the ASDAS with ESR, CRP and PGA. ASDAS correlated well with patient global score (r ranged from 0.65 to 0.72), ESR (r ranged from 0.57 to 0.81) and CRP (r ranged from 0.51 to 0.70) both at baseline and in the changes following therapy33. Our study revealed comparable good correlation of the ASDAS with ESR and CRP and PGA, and better correlation with PGA.

The Bengali version of the ASDAS showed excellent internal consistency (Cronbach's alpha=0.703). The test-retest reliability was also excellent (ICC=0.98).

**Conclusion:**

The adapted Bengali version of the ASDAS demonstrates acceptable psychometric properties, that is, content validity, construct validity, internal consistency and test-retest reliability in Bangladeshi adult patients with axial spondyloarthritis.
References:

1. Calin A, Taurog J. Spondyloarthritides. New York: Oxford Univ Pr; 1998:3-347.
2. van der Linden SJ, van der Heijde D. Ankylosing spondylitis. Rheum Dis Clin North Am. 1998; 24(4):663-76.
3. Yu D. Spondylarthropathies. In: Ruddy S, Harris ED, Sledge CB, eds. Kelley’s Textbook of Rheumatology. 6th ed. Philadelphia: WB Saunders; 2000:1039-53.
4. Khan MA. Spondyloarthropathies. Rheum Dis Clin North Am. 1992; 18:1-276.
5. Moll JM, Wright V. Association between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behcet’s syndrome. Medicine (Baltimore) 1974; 53: 343-64.
6. Cassidy JT, Petty RE, eds. Textbook of Pediatric Rheumatology. 4th ed. Philadelphia: WB Saunders; 2001.
7. Khan MA, van der Linden SM. A wider spectrum of spondyloarthropathies. Semin Arthritis Rheum. 1990; 20:107-13.
8. Zeidler H, Mau W, Khan MA. Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am. 1992; 18:187-202.
9. Olivieri I, Salvarani C, Cantini F, Ciancio G, Padula A. Ankylosing spondylitis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol. 2001; 13:280-4.
10. Malaviya AN, Rawat R, Agrawal N, Patil NS. The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis. The Tangled Skein of Rheumatology. International Journal of Rheumatology. Int J Rheumatol. 2017; 18:247-94.
11. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. New approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol1994; 21: 2286-91.
12. Machado P, van der Heijde D. How to measure disease activity in axial spondyloarthritis? Curr Opin Rheumatol 2011; 23: 339-45.
13. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Assessment of spondyloarthritis international society: Development of an ASAS endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:18-24.
14. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. Assessment of spondyloarthritis international society (ASAS): ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:1811-8.
15. Braun J, Kiltz U, Baraliakos X, van der Heijde D. Optimisation of rheumatology assessments-the actual situation in axial spondyloarthritis including ankylosing spondylitis. Clin Exp Rheumatol. 2014; 32 (Suppl. 85): S96-S104.
16. Machado P, Landewe R. Spondyloarthritis. Is it time to replace BASDAI with ASDAS? Nat Rev Rheumatol. 2013; 9:388-90.
17. Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014; 73:1455-61.
18. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Assessment of spondyloarthritis international society: Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011; 70:47-53.
19. van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, et al. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology (Oxford) 2012; 51:1894-1905.
20. Vastesaeger N, Cuyssens BV, Mulero J, Gracácos Masmitjá J, Zorcó P, Almodovar R, et al. REGISPORTS ER Working group: ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Rheumatol Clin 2014; Jul-Aug; 10(4):204-9.
21. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kaufmann C, Rødevand E, et al. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria. Rheumatology (Oxford);2012; 51: 1479-83.
22. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis; 2011; 70:973-81.
23. Machado P, Landewe RB, Braun J, Baraliakos X, Hermann KG, Hsu B, et al. MRI in?ammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis; 2012; 71:2002-5.
24. Pedersen SJ, Sorensen IJ, Garnere P, Johansen JS, Madsen OR, Tvende N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF-a inhibitors. Ann Rheum Dis; 2011; 70:1375-81.
25. Pedersen SJ, Sorensen IJ, Hermann KG, Madsen OR, Tvende N, Hansen MS, et al.: Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis; 2010; 69:1065-71.
26. Song JH, Rudwaleit M, Listing J, Sieper J. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis; 2009; 68:1701-7.
27. Eder L, Chandran V, Shu H, Cook RJ, Gladman DD. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis. 2010; 69:2160-4.
28. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000 Dec 15; 25(24):3186-91.
29. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27: 361-8.
30. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68 (Suppl 2): i1-i44.
31. Sieper J, van der Heijde D, Landewe R, Brandt J, Burgos-Vargas R, Collantes-Estevez E, et al. New criteria ´ for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of Spondyloarthritis international Society (ASAS). Annals of the Rheumatic Diseases 2009; 68(6):784-88.
32. Bennett P, Burch T. Population studies of the rheumatic diseases. In: Ruddy S, Harris ED, Sledge CB, eds. Kelley's Textbook of Rheumatology. 6th ed. Philadelphia: WB Saunders; 2000:1039-53.